Literature DB >> 22083086

Pharmacotherapy: vandetanib-a new therapeutic option in advanced medullary thyroid cancer.

Linda Koch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22083086     DOI： 10.1038/nrendo.2011.198

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Authors:  Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.